Codexis Turns Profitable After 19 Years But Investors Still Lose

Codexis (CDXS) reported Q4 2025 earnings on March 11, 2026, surpassing expectations with a $0.11 EPS beat (vs. $-0.13 loss) and $38.9M revenue (up 81.3% YoY). The company raised 2026 guidance to $72–76M, signaling confidence in ECO Synthesis scaling and CDMO partnerships.

Revenue

The total revenue of Codexis increased by 81.3% to $38.91 million in 2025 Q4, up from $21.46 million in 2024 Q4.

Earnings/Net Income

Codexis returned to profitability with EPS of $0.11 in 2025 Q4, reversing from a loss of $0.13 per share in 2024 Q4 (183.8% positive change). Meanwhile, the company achieved a remarkable turnaround with net income of $9.60 million in 2025 Q4, representing a 192.5% positive swing from the net loss of $-10.38 million in 2024 Q4. The Company has sustained losses for 19 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The EPS and net income reflect a significant operational and financial recovery.

Price Action

The stock price of Codexis has edged up 1.60% during the latest trading day, has surged 17.59% during the most recent full trading week, and has dropped 4.51% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Codexis (CDXS) shares after their revenue raise quarter-over-quarter on the financial report released date and holding for 30 days resulted in a significant underperformance. The strategy yielded an 86.38% loss, vastly underperforming the benchmark return of 57.31%. The excess return was -143.69%, and the CAGR was -39.50%, indicating a substantial decline in value over the 3-year period.

CEO Commentary

Dr. Alison Moore, President and Chief Executive Officer, emphasized Codexis’ 2025 progress in scaling the ECO Synthesis platform, achieving 10-gram siRNA synthesis and 100-gram production, with a goal of 0.5 kg by year-end. She highlighted partnerships with CDMOs like Bachem and Axolabs, noting these agreements validate the platform’s potential to address siRNA manufacturing scalability. Moore underscored the $2B total addressable market by 2030 and emphasized stereoisomer control innovation as a competitive edge. She acknowledged workforce realignments to fund GMP facility construction, stating the Merck $37.8M agreement strengthened liquidity. The tone was optimistic, stressing 2026 as a year to demonstrate ECO Synthesis’ value through contracts, licensing deals, and commercial supply agreements.

Guidance

Codexis expects 2026 revenue of $72–76 million, with growth weighted toward the second half. The company projects stable 64% product gross margins, driven by higher-margin ECO Synthesis services and small molecule biocatalysis. Capital expenditures will partially offset by cost savings from workforce realignments, funding the GMP plant retrofit (operational by 2027). Cash reserves of $78.2 million are expected to fund operations through 2027. Qualitative guidance includes advancing stereoisomer control commercialization and securing licensing deals, with 55 sales pipeline opportunities.

Additional News

Codexis expanded CDMO partnerships in 2025, securing agreements with Bachem, Nitto Avecia, and Axolabs to scale siRNA manufacturing via its ECO Synthesis platform. The $37.8M technology transfer deal with Merck bolstered liquidity and validated the platform’s commercial potential. Management emphasized stereoisomer control innovation as a key differentiator, with plans to present preclinical data in 2026. Workforce realignments and GMP facility construction underscore operational priorities, while 55 pipeline opportunities highlight growth potential in RNA medicine and biocatalysis.